Two hours. That’s how long it will take to go from opening a website to getting a GLP-1 prescription in your mailbox in 2026. It comes with a questionnaire (asking about your height and weight, without checking the facts), a remote review by a clinician you’ve never met, and confirmation.
A prescription means that a doctor has looked at you, assessed the situation and determined that medical intervention is necessary.
But the woman who fills out the short questionnaire on the phone is not sick. She just wants to fit back into the jeans she hasn’t worn in two years. He’s done his research, he can afford it medicineand she spent years managing her body the hard way, calculating, restricting, working, and showing much less for it. That way, she doesn’t feel sick when the confirmation arrives in her inbox. She feels like a woman who finally has access to something that actually works.
Do we leave it at that, or do we ask what it means that access to powerful prescription drugs now requires nothing more than a credit card and a WiFi connection?
When semaglutide was first approved for weight managementyou needed a body mass index (BMI) of 30 or higher or a documented medical condition. The drug is intended for people whose weight is determined as a chronic disease. Then the thresholds disappeared. In March 2024, the Food and Drug Administration removed the specific BMI requirement from the semaglutide label, in part to correct the limitations of BMI as a measurement tool, a metric that researchers have long argued was developed in European populations and does not translate well across different authorities. Tirzepatide followed seven months later.
The industry that was waiting for it entered that open door. Amalgamated pharmacies produced cheaper unbranded versions, telehealth platforms built businesses around them, and suddenly ads were everywhere, aimed not at people who had been struggling with obesity for decades, but at thin, young women looking to shed a few pounds by summer.
You know what you want. Do you know why?
A telephone health questionnaire asks about your weight, which may be completely within the normal range. He doesn’t ask what your mother said about her body when you were growing up.
that memoryfor many women, that’s where the story really begins. And yet the desire to lose weight among women who do not need to lose weight is so established that it hardly registers as a story. In 2025, 61 percent of American women say they want to lose weight, a number that has remained remarkably stable since 1951, regardless of what culture tells women about it. body positivity.
The desire to be thin is felt by the individual, but research shows that it is mostly borrowed. So when you think of informed consent as a simple thing you read, understand, and decide, it’s worth pausing about the underlying assumption: the desire itself is self-generated. And for body imagebecause what you feel in front of the mirror is almost never completely true.
Women who have internalized the cultural ideal of thinness pursue it because they associate being thin with psychological rewards. confidence and happinessand social favors for better relationships and professional success. And it is deeper than effort. Research consistently shows that being overweight is culturally associated with laziness and lack of discipline, unhealthy associations, and everything to do with moral judgment. Researchers have found that body dissatisfaction and the desire to lose weight are primarily caused by the internalization of these cultural ideals, rather than an objective evaluation of your body. A woman who ordered her GLP-1 online and did her research is still making decisions inside a story she didn’t write.
Her choice is real, but the question of what is actually being treated. Because if a size 4 qualifies for a prescription, and the desire to downsize is statistically more about social norms than health, then what we’ve created is a very effective delivery mechanism for a very old drug. anxietythis time in pill form.
The price no one will tell you
A confirmation will arrive in your inbox. What it doesn’t include is talking about how this drug may be costing you psychologically rather than financially.
Research on mental health and GLP-1 is still inconsistent with prescriptions. A large cohort study in 2024 showed a significant association between GLP-1 therapy and increased risk of major disease. depression and anxiety. In a 2025 document, it was suggested that the drug can reduce depression and suicide idea especially in people who have a genetic predisposition to low dopamine function Other studies have not found mental risk, and some even showed modest reductions in depressive symptoms. The science isn’t settled, and it’s rarely part of the conversation before you sign up.
Loiki was never free. You always paid for it with some currency, limitation, obsession, time, self-criticism. The question that GLP-1 raises is whether you have just found an efficient payment method and whether efficiency is the same as security.
Who decides this? You are ideal. But only if someone asks you questions first, the page is left.
